Clinical lung cancer · 2025
Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bazzi Hayat, Thuo Nicholas, Sravanam Sruthi, Chen Wei, Abda Faten, Alqased Aula, Chindhade Swara, Snounu Yasmin, Yaakov Sadia, Barton Colin, Thompson Matthew J, Culver Kenneth W, Achkar Morhaf Al
Аннотация
BACKGROUND: Anaplastic Lymphoma Kinase (ALK)-positive nonsmall cell lung cancer (NSCLC) primarily affects younger, nonsmoking individuals. Tyrosine kinase inhibitors (TKIs) have improved survival. While timely diagnosis and TKI initiation are critical, global data on diagnostic and treatment timelines remain scarce. This study examines key intervals from the first medical visit to diagnosis and treatment, and factors linked to delays.
METHODS: The ALK Life Study is a longitudinal observational study of ALK-positive NSCLC patients, with data collected via online surveys from September 2022 to November 2024. Patients were recruited through support groups, newsletters, and oncologist referrals. Descriptive statistics and multivariable regression identified factors influencing timelines.
RESULTS: A total of 1288 patients from 71 countries completed the survey. The median age at diagnosis was 52 years, 52% from the U.S., and 28% with a smoking history. For all patients, the median time from first medical visit to diagnosis (DOD) was 45 days (IQR: 16-120). For stage IIIC/IV patients, the median time from diagnosis to TKI treatment (DDT) was 30 days (IQR: 17-49). Older ages at the first visit were linked to shorter DOD, while more symptoms increased DOD. For advanced-stage patients, older age, GERD, and high blood pressure prolonged DDT, while coughing up blood and voice changes shortened it. Recent diagnosis year and residence in Canada were tied to shorter DDT.
CONCLUSIONS: Younger age, specific comorbidities, nonspecific symptoms, and geographic factors lengthen intervals to diagnosis and treatment. Raising awareness of ALK-positive NSCLC in younger patients could improve diagnosis timelines and outcomes.
METHODS: The ALK Life Study is a longitudinal observational study of ALK-positive NSCLC patients, with data collected via online surveys from September 2022 to November 2024. Patients were recruited through support groups, newsletters, and oncologist referrals. Descriptive statistics and multivariable regression identified factors influencing timelines.
RESULTS: A total of 1288 patients from 71 countries completed the survey. The median age at diagnosis was 52 years, 52% from the U.S., and 28% with a smoking history. For all patients, the median time from first medical visit to diagnosis (DOD) was 45 days (IQR: 16-120). For stage IIIC/IV patients, the median time from diagnosis to TKI treatment (DDT) was 30 days (IQR: 17-49). Older ages at the first visit were linked to shorter DOD, while more symptoms increased DOD. For advanced-stage patients, older age, GERD, and high blood pressure prolonged DDT, while coughing up blood and voice changes shortened it. Recent diagnosis year and residence in Canada were tied to shorter DDT.
CONCLUSIONS: Younger age, specific comorbidities, nonspecific symptoms, and geographic factors lengthen intervals to diagnosis and treatment. Raising awareness of ALK-positive NSCLC in younger patients could improve diagnosis timelines and outcomes.